isoniazid has been researched along with Chronic Kidney Failure in 59 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 76-year-old man complicated with end-stage renal disease had latent tuberculosis infection (LTBI), and isoniazid (INH) 300 mg daily was started to prevent reactivation of LTBI before using biologic agents for rheumatoid arthritis." | 8.98 | Rhabdomyolysis Induced by Isoniazid in a Patient with Rheumatoid Arthritis and End-stage Renal Disease: A Case Report and Review of the Literature. ( Fujio, K; Komai, T; Sumitomo, S; Teruya, S, 2018) |
| "The consequences of once-weekly rifapentine plus isoniazid for 3 months (3HP) against latent tuberculosis infections in hemodialysis patients have not been studied before." | 7.91 | Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events. ( Chen, TC; Chen, YH; Chiu, YW; Hsieh, MH; Hwang, SJ; Lin, SY; Lu, PL, 2019) |
| "In a case-control study of 92 Indian patients, 46 with active tuberculosis (cases) and 46 tuberculin reactors without the disease (control subjects), significantly more control subjects than patients had prior adequate isoniazid chemoprophylaxis." | 7.68 | The benefits of isoniazid chemoprophylaxis and risk factors for tuberculosis among Oglala Sioux Indians. ( Leonardson, G; Mori, MA; Welty, TK, 1992) |
| "A 76-year-old man complicated with end-stage renal disease had latent tuberculosis infection (LTBI), and isoniazid (INH) 300 mg daily was started to prevent reactivation of LTBI before using biologic agents for rheumatoid arthritis." | 4.98 | Rhabdomyolysis Induced by Isoniazid in a Patient with Rheumatoid Arthritis and End-stage Renal Disease: A Case Report and Review of the Literature. ( Fujio, K; Komai, T; Sumitomo, S; Teruya, S, 2018) |
| "The consequences of once-weekly rifapentine plus isoniazid for 3 months (3HP) against latent tuberculosis infections in hemodialysis patients have not been studied before." | 3.91 | Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events. ( Chen, TC; Chen, YH; Chiu, YW; Hsieh, MH; Hwang, SJ; Lin, SY; Lu, PL, 2019) |
| "Three dialysis patients with extrapulmonary tuberculosis developed confusion 4-14 days after commencement of treatment with anti-tuberculosis drugs, despite the use of prophylactic pyridoxine." | 3.68 | Isoniazid induced encephalopathy in dialysis patients. ( Cheng, IK; Cheung, WC; Ip, M; Lo, CY; Lo, WK, 1993) |
| "In a case-control study of 92 Indian patients, 46 with active tuberculosis (cases) and 46 tuberculin reactors without the disease (control subjects), significantly more control subjects than patients had prior adequate isoniazid chemoprophylaxis." | 3.68 | The benefits of isoniazid chemoprophylaxis and risk factors for tuberculosis among Oglala Sioux Indians. ( Leonardson, G; Mori, MA; Welty, TK, 1992) |
| "Treatment of tuberculosis in a hemodialysis patient with isoniazid, rifampin, and pyrazinamide resulted in the development of acute cerebellar dysfunction." | 3.68 | Cerebellar syndrome caused by isoniazid. ( Blumberg, EA; Gil, RA, 1990) |
| "Screening for and treatment of latent tuberculosis (TB) in patients with end-stage kidney disease (ESKD) are recommended." | 3.11 | Comparison of three short-course rifamycin-based regimens for the prevention of tuberculosis in patients with end-stage kidney disease: Study protocol for a randomised clinical trial (RIFAKiD-TB trial). ( Anibarro, L; Barcala, JM; De Souza-Galvao, ML; Gijon, P; Grijota, MD; Luque, R; Perez-Recio, S; Sanchez, F; Santin, M, 2022) |
| "Patients of end stage renal disease (ESRD) taken for RT formed the subjects of study." | 2.71 | Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient. ( Agarwal, SK; Bhowmik, D; Dash, SC; Gupta, S; Tiwari, SC, 2004) |
| "We present a case of isoniazid-induced encephalopathy in a haemodialysis patient." | 2.61 | Isoniazid-induced encephalopathy in an end-stage renal disease patient - A case report and literature review. ( Low, JM; Wong, KW, 2019) |
| " Incidents of systemic adverse reactions (SARs) and treatment interruption rates in an elderly group (≥60 years old) and a young group (<60 years old) were analyzed." | 1.56 | Safety and treatment completion of latent tuberculosis infection treatment in the elderly population-A prospective observational study in Taiwan. ( Chen, CY; Feng, JY; Huang, WC; Lee, SS; Li, CP; Lin, CB; Lin, SM; Pan, SW; Shu, CC; Su, WJ; Tung, CL; Wang, TY; Wei, YF, 2020) |
| " However, their neurotoxicity could cause adverse effect and the patients with end-stage renal disease are especially vulnerable due to the reduction in renal drug clearance." | 1.48 | Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis. ( Chen, Y; Li, H; Peng, H; Si, M, 2018) |
| "He experienced a sense of drunkenness when he received isoniazid, apparently not in association with any of the other antituberculosis drugs given." | 1.39 | [Drunkenness caused by isoniazid in a tuberculosis patient with extrapulmonary lesions on hemodialysis: a case report]. ( Fukasawa, K; Honda, T; Miyashita, Y; Saiki, M; Sano, K; Sogami, Y, 2013) |
| "A 50-year-old ESRD who received LUR renal graft abroad." | 1.34 | Fatal hemorrhagic intracranial TB in a renal transplant recipient despite INH prophylaxis. ( Abutaleb, N; Adem, M; Afifi, H; Fallata, S; Hamza, A; Obaideen, A; Younis, S; Zakaria, M, 2007) |
| "Tuberculosis is an endemic disease in our countries." | 1.30 | [Tuberculosis among hemodialysis patients in Dakar, apropos of 2 cases]. ( Bao, O; Diouf, B; Diouf, ML; Ka, MM; Mbengue, M; Moreira-Diop, T; Niang, A; Pouye, A, 1998) |
| "The immune deficiencies of chronic renal failure and diabetes mellitus are suspected predisposing factors to the development of miliary tuberculosis in these patients." | 1.26 | Unusual presentation of tuberculosis in chronic hemodialysis patients. ( Amedia, C; Oettinger, CW, 1977) |
| " If INH is to be used in the presence of renal failure, individual half life estimations should be performed in order to determine dosage frequency." | 1.26 | Isoniazid pharmacokinetics in patients in chronic renal failure. ( Buchanan, N; Gold, CH; Moodley, GP; Strickwold, B; Tringham, V; Viljoen, M, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (42.37) | 18.7374 |
| 1990's | 9 (15.25) | 18.2507 |
| 2000's | 9 (15.25) | 29.6817 |
| 2010's | 12 (20.34) | 24.3611 |
| 2020's | 4 (6.78) | 2.80 |
| Authors | Studies |
|---|---|
| Santin, M | 1 |
| Perez-Recio, S | 1 |
| Grijota, MD | 1 |
| Anibarro, L | 1 |
| Barcala, JM | 1 |
| De Souza-Galvao, ML | 1 |
| Gijon, P | 1 |
| Luque, R | 1 |
| Sanchez, F | 1 |
| Low, JM | 1 |
| Wong, KW | 1 |
| Feng, JY | 1 |
| Huang, WC | 1 |
| Lin, SM | 1 |
| Wang, TY | 1 |
| Lee, SS | 1 |
| Shu, CC | 1 |
| Pan, SW | 1 |
| Chen, CY | 1 |
| Lin, CB | 1 |
| Wei, YF | 1 |
| Tung, CL | 1 |
| Li, CP | 1 |
| Su, WJ | 1 |
| Lee, IH | 1 |
| Kim, SG | 1 |
| Kwon, JG | 1 |
| Yang, CS | 1 |
| Kang, S | 1 |
| Kim, MK | 1 |
| Ahn, DJ | 1 |
| Chiang, LY | 1 |
| Baumann, B | 1 |
| Romanowski, K | 1 |
| Kumar, D | 1 |
| Campbell, JR | 1 |
| Djurdjev, O | 1 |
| Morshed, M | 1 |
| Sekirov, I | 1 |
| Cook, VJ | 1 |
| Levin, A | 1 |
| Johnston, JC | 1 |
| Constantinescu, SM | 1 |
| Buysschaert, B | 1 |
| Haufroid, V | 1 |
| Broly, F | 1 |
| Jadoul, M | 1 |
| Morelle, J | 1 |
| Komai, T | 1 |
| Sumitomo, S | 1 |
| Teruya, S | 1 |
| Fujio, K | 1 |
| Si, M | 1 |
| Li, H | 1 |
| Chen, Y | 1 |
| Peng, H | 1 |
| Lin, SY | 1 |
| Chiu, YW | 1 |
| Lu, PL | 1 |
| Hwang, SJ | 1 |
| Chen, TC | 1 |
| Hsieh, MH | 1 |
| Chen, YH | 1 |
| Kurane, K | 1 |
| Goto, M | 1 |
| Sano, K | 2 |
| Noguchi, K | 1 |
| Tamura, D | 1 |
| Yamagata, T | 1 |
| Saiki, M | 1 |
| Honda, T | 1 |
| Sogami, Y | 1 |
| Fukasawa, K | 1 |
| Miyashita, Y | 1 |
| Niepolski, L | 1 |
| Grzegorzewska, AE | 1 |
| Getahun, H | 1 |
| Matteelli, A | 1 |
| Abubakar, I | 1 |
| Aziz, MA | 1 |
| Baddeley, A | 1 |
| Barreira, D | 1 |
| Den Boon, S | 1 |
| Borroto Gutierrez, SM | 1 |
| Bruchfeld, J | 1 |
| Burhan, E | 1 |
| Cavalcante, S | 1 |
| Cedillos, R | 1 |
| Chaisson, R | 1 |
| Chee, CB | 1 |
| Chesire, L | 1 |
| Corbett, E | 1 |
| Dara, M | 1 |
| Denholm, J | 1 |
| de Vries, G | 1 |
| Falzon, D | 1 |
| Ford, N | 1 |
| Gale-Rowe, M | 1 |
| Gilpin, C | 1 |
| Girardi, E | 1 |
| Go, UY | 1 |
| Govindasamy, D | 1 |
| D Grant, A | 1 |
| Grzemska, M | 1 |
| Harris, R | 1 |
| Horsburgh, CR | 1 |
| Ismayilov, A | 1 |
| Jaramillo, E | 1 |
| Kik, S | 1 |
| Kranzer, K | 1 |
| Lienhardt, C | 1 |
| LoBue, P | 1 |
| Lönnroth, K | 1 |
| Marks, G | 1 |
| Menzies, D | 1 |
| Migliori, GB | 1 |
| Mosca, D | 1 |
| Mukadi, YD | 1 |
| Mwinga, A | 1 |
| Nelson, L | 1 |
| Nishikiori, N | 1 |
| Oordt-Speets, A | 1 |
| Rangaka, MX | 1 |
| Reis, A | 1 |
| Rotz, L | 1 |
| Sandgren, A | 1 |
| Sañé Schepisi, M | 1 |
| Schünemann, HJ | 1 |
| Sharma, SK | 1 |
| Sotgiu, G | 1 |
| Stagg, HR | 1 |
| Sterling, TR | 1 |
| Tayeb, T | 1 |
| Uplekar, M | 1 |
| van der Werf, MJ | 1 |
| Vandevelde, W | 1 |
| van Kessel, F | 1 |
| van't Hoog, A | 1 |
| Varma, JK | 1 |
| Vezhnina, N | 1 |
| Voniatis, C | 1 |
| Vonk Noordegraaf-Schouten, M | 1 |
| Weil, D | 1 |
| Weyer, K | 1 |
| Wilkinson, RJ | 1 |
| Yoshiyama, T | 1 |
| Zellweger, JP | 1 |
| Raviglione, M | 1 |
| Hamadah, AM | 1 |
| Beaulieu, LM | 1 |
| Wilson, JW | 1 |
| Aksamit, TR | 1 |
| Gregoire, JR | 1 |
| Williams, AW | 1 |
| Dillon, JJ | 1 |
| Albright, RC | 1 |
| Onuigbo, M | 1 |
| Iyer, VK | 1 |
| Hickson, LJ | 1 |
| Chaitanya, V | 1 |
| Sangeetha, B | 1 |
| Reddy, MH | 1 |
| Venkata Kumar, AC | 1 |
| Ram, R | 1 |
| Sivakumar, V | 1 |
| El Kabbaj, D | 1 |
| Aatif, M | 1 |
| Moussa, LA | 1 |
| Khassouani, CE | 1 |
| Oualim, Z | 1 |
| de Oliveira, JL | 1 |
| da Silva Junior, GB | 1 |
| Daher, Ede F | 1 |
| Altíparmak, MR | 1 |
| Pamuk, ON | 1 |
| Pamuk, GE | 1 |
| Ataman, R | 1 |
| Serdengeçti, K | 1 |
| Wang, HY | 1 |
| Chien, CC | 1 |
| Chen, YM | 1 |
| Huang, CC | 1 |
| Hung, SC | 1 |
| Yang, WC | 1 |
| Tarng, DC | 1 |
| Agarwal, SK | 1 |
| Gupta, S | 1 |
| Dash, SC | 1 |
| Bhowmik, D | 2 |
| Tiwari, SC | 2 |
| Bal, AM | 1 |
| Kocabay, G | 1 |
| Erelel, M | 1 |
| Tutkun, IT | 1 |
| Ecder, T | 1 |
| Mahapatra, HS | 1 |
| Mahajan, S | 1 |
| Abutaleb, N | 1 |
| Obaideen, A | 1 |
| Hamza, A | 1 |
| Zakaria, M | 1 |
| Afifi, H | 1 |
| Fallata, S | 1 |
| Younis, S | 1 |
| Adem, M | 1 |
| Titarenko, OT | 3 |
| Vakhmistrova, TI | 3 |
| Perova, TL | 3 |
| Morozov, NV | 1 |
| Andrew, OT | 1 |
| Schoenfeld, PY | 1 |
| Hopewell, PC | 1 |
| Humphreys, MH | 1 |
| Mitchison, DA | 1 |
| Ellard, GA | 2 |
| Brandspigel, K | 1 |
| Mattern, WD | 1 |
| Kim, YG | 1 |
| Shin, JG | 1 |
| Shin, SG | 1 |
| Jang, IJ | 1 |
| Kim, S | 1 |
| Lee, JS | 1 |
| Han, JS | 1 |
| Cha, YN | 1 |
| Siskind, MS | 1 |
| Thienemann, D | 1 |
| Kirlin, L | 1 |
| Cheung, WC | 1 |
| Lo, CY | 1 |
| Lo, WK | 1 |
| Ip, M | 1 |
| Cheng, IK | 1 |
| Iwamatsu, H | 1 |
| Teramura, T | 1 |
| Kikuchi, M | 1 |
| Yoshida, K | 1 |
| Diouf, B | 1 |
| Niang, A | 1 |
| Pouye, A | 1 |
| Diouf, ML | 1 |
| Mbengue, M | 1 |
| Ka, MM | 1 |
| Moreira-Diop, T | 1 |
| Bao, O | 1 |
| Bartels, H | 1 |
| Spring, P | 1 |
| Coutts, II | 1 |
| Jegarajah, S | 1 |
| Stark, JE | 1 |
| Papadimitriou, M | 1 |
| Memmos, D | 1 |
| Metaxas, P | 1 |
| Heising, J | 1 |
| Seiferth, J | 1 |
| Chapron, DJ | 1 |
| Blum, MR | 1 |
| Kramer, PA | 1 |
| Amedia, C | 1 |
| Oettinger, CW | 1 |
| Gold, CH | 1 |
| Buchanan, N | 1 |
| Tringham, V | 1 |
| Viljoen, M | 1 |
| Strickwold, B | 1 |
| Moodley, GP | 1 |
| Mori, MA | 1 |
| Leonardson, G | 1 |
| Welty, TK | 1 |
| O'Donoghue, DJ | 1 |
| Short, CD | 1 |
| Gokal, R | 1 |
| Johnson, RW | 1 |
| Blumberg, EA | 1 |
| Gil, RA | 1 |
| Hermann, P | 1 |
| Smith, FW | 1 |
| Catto, GR | 1 |
| MacLeod, M | 1 |
| Rosenberg, JM | 1 |
| Peritore, SP | 1 |
| Anderson, KA | 1 |
| Guzzetti, PJ | 1 |
| Falls, WF | 1 |
| Randall, RE | 1 |
| Sommers, SC | 1 |
| Stacy, WK | 1 |
| Larkin, EG | 1 |
| Still, WJ | 1 |
| Schüler, HW | 1 |
| Röhl, L | 1 |
| Asbach, HW | 1 |
| Möhring, K | 1 |
| Maurer, C | 1 |
| Stöhrer, M | 1 |
| Zeigler, M | 1 |
| Mehls, O | 1 |
| Scharer, K | 1 |
| Steffen, H | 1 |
| Bowersox, DW | 1 |
| Wintebauer, RH | 1 |
| Stewart, GL | 1 |
| Orme, B | 1 |
| Barron, E | 1 |
| Cohen, H | 1 |
| Langendorf, R | 1 |
| Pick, A | 1 |
| Reidenberg, MM | 1 |
| Shear, L | 1 |
| Cohen, RV | 1 |
| Jungbluth, H | 1 |
| Turpin, R | 1 |
| Bergogne-Berezin, E | 1 |
| Caille, B | 1 |
| Salmon-Bonnereau, D | 1 |
| Ogg, CS | 1 |
| Toseland, PA | 1 |
| Cameron, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of 3-month Once-weekly Isoniazid Plus Rifapentine, 4-month Daily Rifampicin, and 3-month Daily Isoniazid Plus Rifampicin for the Treatment Latent Tuberculosis in Patients With End-stage Kidney Disease: A Randomised Clinical Trial[NCT05021731] | Phase 4 | 225 participants (Anticipated) | Interventional | 2022-04-01 | Not yet recruiting | ||
| URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299] | Phase 4 | 302 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
| One-month Latent Tuberculosis Treatment for Renal Transplant Candidates[NCT05411744] | Phase 4 | 25 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | percent (Number) |
|---|---|
| INH and Vitamin B6 | 8.3 |
Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| INH and Vitamin B6 | 32 |
Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 80 |
Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 308 |
INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation
| Intervention | pmol/mg (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 36.0 | 37.8 |
Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 31.3 | 43.9 |
"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH
| Intervention | days (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 30 | 30 |
The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At 3 months72558043 | At 6 months72558043 | |||||||||||
| Excellent | Very good | Good | Fair | Poor | Very poor | |||||||
| INH and Vitamin B6 | 160 | |||||||||||
| INH and Vitamin B6 | 79 | |||||||||||
| INH and Vitamin B6 | 38 | |||||||||||
| INH and Vitamin B6 | 2 | |||||||||||
| INH and Vitamin B6 | 124 | |||||||||||
| INH and Vitamin B6 | 90 | |||||||||||
| INH and Vitamin B6 | 41 | |||||||||||
| INH and Vitamin B6 | 4 | |||||||||||
| INH and Vitamin B6 | 0 | |||||||||||
| INH and Vitamin B6 | 1 | |||||||||||
6 reviews available for isoniazid and Chronic Kidney Failure
| Article | Year |
|---|---|
Isoniazid-induced encephalopathy in an end-stage renal disease patient - A case report and literature review.
Topics: Antitubercular Agents; Brain Diseases; Female; Humans; Isoniazid; Kidney Failure, Chronic; Middle Ag | 2019 |
Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy - case report and literature review.
Topics: Aged; Antitubercular Agents; Arylamine N-Acetyltransferase; Brain Diseases; Humans; Isoniazid; Kidne | 2017 |
Rhabdomyolysis Induced by Isoniazid in a Patient with Rheumatoid Arthritis and End-stage Renal Disease: A Case Report and Review of the Literature.
Topics: Aged; Anti-Bacterial Agents; Antitubercular Agents; Arthritis, Rheumatoid; Humans; Isoniazid; Kidney | 2018 |
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
Topics: Antirheumatic Agents; Antitubercular Agents; Coinfection; Comorbidity; Disease Management; Drug User | 2015 |
Isoniazid-induced neurotoxicity in chronic dialysis patients: report of three cases and a review of the literature.
Topics: Aged; Aged, 80 and over; Female; Humans; Isoniazid; Kidney Failure, Chronic; Male; Middle Aged; Nerv | 1993 |
[Ocular toxicity of ethambutol].
Topics: Aged; Aminosalicylic Acids; Capreomycin; Chemical Phenomena; Chemistry; Color Perception; Drug Thera | 1971 |
3 trials available for isoniazid and Chronic Kidney Failure
| Article | Year |
|---|---|
Comparison of three short-course rifamycin-based regimens for the prevention of tuberculosis in patients with end-stage kidney disease: Study protocol for a randomised clinical trial (RIFAKiD-TB trial).
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Kidney Failure, Chronic; | 2022 |
Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient.
Topics: Antitubercular Agents; Female; Humans; Isoniazid; Kidney Failure, Chronic; Kidney Transplantation; M | 2004 |
Decreased acetylation of isoniazid in chronic renal failure.
Topics: Acetylation; Adolescent; Adult; Evaluation Studies as Topic; Female; Humans; Isoniazid; Kidney Failu | 1993 |
50 other studies available for isoniazid and Chronic Kidney Failure
| Article | Year |
|---|---|
Safety and treatment completion of latent tuberculosis infection treatment in the elderly population-A prospective observational study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; In | 2020 |
Intestinal tuberculosis in a patient with end-stage renal disease on hemodialysis: A case report.
Topics: Anorexia; Antitubercular Agents; Drug Combinations; Ethambutol; Humans; Isoniazid; Kidney Failure, C | 2020 |
Latent Tuberculosis Therapy Outcomes in Dialysis Patients: A Retrospective Cohort.
Topics: Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cohort Studies; Exanthema; Fema | 2021 |
Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis.
Topics: Adult; Antitubercular Agents; Ethambutol; Humans; Isoniazid; Kidney Failure, Chronic; Male; Optic Ne | 2018 |
Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, C | 2019 |
Pharmacokinetics of Isoniazid-induced Rhabdomyolysis in a Girl.
Topics: Antitubercular Agents; Arthritis, Rheumatoid; Female; Humans; Isoniazid; Kidney Failure, Chronic; Li | 2018 |
[Drunkenness caused by isoniazid in a tuberculosis patient with extrapulmonary lesions on hemodialysis: a case report].
Topics: Alcoholic Intoxication; Antitubercular Agents; Humans; Isoniazid; Kidney Failure, Chronic; Male; Mid | 2013 |
[A positive test QuantiFERON-TB Gold In-Tube in a patient treated with continuous ambulatory peritoneal dialysis].
Topics: Aged; Antitubercular Agents; Drug Administration Schedule; Female; Humans; Isoniazid; Kidney Failure | 2014 |
Tolerability and Healthcare Utilization in Maintenance Hemodialysis Patients Undergoing Treatment for Tuberculosis-Related Conditions.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Cohort Studies; Emergency Medical Services; F | 2016 |
Isoniazid cerebellitis in a peritoneal dialysis patient.
Topics: Antitubercular Agents; Cerebellar Diseases; Cerebellar Nuclei; Humans; Isoniazid; Kidney Failure, Ch | 2016 |
Measurement of plasma levels of isoniazid for dose adjustment in the hemodialysis patients.
Topics: Antitubercular Agents; Comorbidity; Half-Life; Humans; Isoniazid; Kidney Failure, Chronic; Renal Dia | 2009 |
Tuberculosis-associated chronic kidney disease.
Topics: Antitubercular Agents; Ethambutol; Fever; Humans; Isoniazid; Kidney Failure, Chronic; Male; Pyrazina | 2011 |
Is isoniazid ototoxic in patients undergoing hemodialysis?
Topics: Adult; Aged; Antitubercular Agents; Female; Hearing Loss; Humans; Isoniazid; Kidney Failure, Chronic | 2002 |
Encephalopathy caused by isoniazid in a patient with end stage renal disease with extrapulmonary tuberculosis.
Topics: Antitubercular Agents; Humans; Isoniazid; Kidney Failure, Chronic; Male; Middle Aged; Neurotoxicity | 2003 |
Fistulizing TB peritonitis during CAPD.
Topics: Adult; Antitubercular Agents; Ascitic Fluid; Female; Humans; Isoniazid; Kidney Failure, Chronic; Myc | 2003 |
Isoniazid prophylaxis in end-stage renal disease.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Humans; Isoniazid; Kidney Failure, Chronic; Mycobacte | 2006 |
Optic neuritis and bitemporal hemianopsia associated with isoniazid treatment in end-stage renal failure.
Topics: Adult; Antitubercular Agents; Combined Modality Therapy; Drug Therapy, Combination; Ethambutol; Hemi | 2006 |
Isoniazid induced acute bilateral cerebellar syndrome in chronic kidney disease.
Topics: Acute Disease; Adult; Antitubercular Agents; Cerebellar Diseases; Female; Humans; Isoniazid; Kidney; | 2007 |
Fatal hemorrhagic intracranial TB in a renal transplant recipient despite INH prophylaxis.
Topics: Antitubercular Agents; Fatal Outcome; Follow-Up Studies; Humans; Intracranial Hemorrhages; Isoniazid | 2007 |
Tuberculosis in chronic renal failure.
Topics: Ethambutol; Humans; Isoniazid; Kidney Failure, Chronic; Mycobacterium avium; Rifampin; Tuberculosis | 1980 |
[Urinary excretion of rifampicin in kidney failure when administered alone or together with isoniazid].
Topics: Administration, Oral; Drug Therapy, Combination; Humans; Isoniazid; Kidney Failure, Chronic; Kidney | 1983 |
[Pharmacokinetics of isoniazid in chronic kidney failure].
Topics: Glomerular Filtration Rate; Half-Life; Humans; Isoniazid; Kidney; Kidney Failure, Chronic; Kinetics; | 1983 |
[Dynamics of isoniazid excretion in chronic renal failure].
Topics: Humans; Isoniazid; Kidney Failure, Chronic; Tuberculosis, Renal | 1982 |
Tuberculosis in patients with end-stage renal disease.
Topics: Adult; Aged; Ethambutol; Female; Humans; Immunity, Cellular; Isoniazid; Kidney Failure, Chronic; Mal | 1980 |
Tuberculosis in patients having dialysis.
Topics: Ethambutol; Half-Life; Humans; Isoniazid; Kidney Failure, Chronic; Renal Dialysis; Streptomycin; Tub | 1980 |
Tuberculosis in chronic renal failure.
Topics: Humans; Isoniazid; Kidney Failure, Chronic; Tuberculosis, Pulmonary | 1980 |
Chemotherapy of tuberculosis for patients with renal impairment.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Kidney Failure, Chronic; Pyrazinamide; Rifampi | 1993 |
Isoniazid induced encephalopathy in dialysis patients.
Topics: Adult; Confusion; Female; Humans; Isoniazid; Kidney Failure, Chronic; Middle Aged; Pyridoxine; Renal | 1993 |
[Case of chronic kidney failure with thrombotic thrombocytopenic purpura due to miliary tuberculosis].
Topics: Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid; Kidney Failure, C | 1998 |
[Tuberculosis among hemodialysis patients in Dakar, apropos of 2 cases].
Topics: Adolescent; Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Hallucinations; Hum | 1998 |
Determination of isonicotinic acid hydrazide in serum.
Topics: Aged; Autoanalysis; Chelating Agents; Copper; Half-Life; Humans; Hydrazines; Hydrogen-Ion Concentrat | 1975 |
Tuberculosis in renal transplant recipients.
Topics: Adult; Drug Administration Schedule; Female; Humans; Isoniazid; Kidney Failure, Chronic; Kidney Tran | 1979 |
Tuberculosis in patients on regular haemodialysis.
Topics: Humans; Isoniazid; Kidney Failure, Chronic; Renal Dialysis; Streptomycin; Tuberculosis | 1979 |
[Therapy of urogenital tuberculosis].
Topics: Ambulatory Care; Ethambutol; Female; Humans; Isoniazid; Kidney Failure, Chronic; Pregnancy; Pregnanc | 1978 |
Evidence for a trimodal pattern of acetylation of isoniazid in uremic subjects.
Topics: Acetylation; Alleles; Genes, Regulator; Humans; Isoniazid; Kidney Failure, Chronic; Uremia | 1978 |
Unusual presentation of tuberculosis in chronic hemodialysis patients.
Topics: Diabetic Nephropathies; Diagnostic Errors; Ethambutol; Female; Humans; Isoniazid; Kidney Failure, Ch | 1977 |
Isoniazid pharmacokinetics in patients in chronic renal failure.
Topics: Adult; Creatinine; Female; Half-Life; Humans; Isoniazid; Kidney Failure, Chronic; Male; Renal Dialys | 1976 |
The benefits of isoniazid chemoprophylaxis and risk factors for tuberculosis among Oglala Sioux Indians.
Topics: Adult; Case-Control Studies; Diabetes Complications; Female; Humans; Indians, North American; Isonia | 1992 |
Pancreatic tuberculosis following renal transplantation.
Topics: Ethambutol; Female; Humans; Immunosuppression Therapy; Isoniazid; Kidney Failure, Chronic; Kidney Tr | 1992 |
Cerebellar syndrome caused by isoniazid.
Topics: Aged; Cerebellar Diseases; Female; Humans; Isoniazid; Kidney Failure, Chronic; Pyrazinamide; Pyridox | 1990 |
Treatment of pulmonary tuberculosis in a patient on maintenance haemodialysis.
Topics: Adult; Aminosalicylic Acids; Antitubercular Agents; Humans; Isoniazid; Kidney Failure, Chronic; Male | 1974 |
Drug information: questions and answers.
Topics: Aged; Ampicillin; Contraceptives, Oral; Diuretics; Drug Hypersensitivity; Female; Food Analysis; Gua | 1974 |
Nonhypercalcemic sarcoid nephropathy.
Topics: Adult; Blood Urea Nitrogen; Calcium; Creatinine; Fluorescent Antibody Technique; Humans; Isoniazid; | 1972 |
Experiences in paediatric haemodialysis.
Topics: Acute Kidney Injury; Adolescent; Arteriovenous Shunt, Surgical; Blood Vessels; Child; Child, Prescho | 1972 |
Isoniazid dosage in patients with renal failure.
Topics: Acetylation; Adult; Aged; Creatinine; Female; Half-Life; Humans; Isoniazid; Kidney; Kidney Failure, | 1973 |
Intermittent parasystole--mechanism of protection.
Topics: Aged; Aminosalicylic Acids; Arrhythmias, Cardiac; Arteriosclerosis; Cerebrovascular Disorders; Coron | 1973 |
Elimination of isoniazid in patients with impaired renal function.
Topics: Adolescent; Adult; Age Factors; Aged; Blood Urea Nitrogen; Creatinine; Female; Humans; Isoniazid; Ki | 1973 |
[Isoniazid dosage in renal insufficiency].
Topics: Humans; Isoniazid; Kidney Failure, Chronic; Tuberculosis, Pulmonary | 1971 |
[The significance of isoniazid metabolism in genetic studies. Anomalies encountered in trisomy 21 patients].
Topics: Acute Kidney Injury; Age Factors; Chromosomes, Human, 21-22 and Y; Genotype; Humans; Isoniazid; Kidn | 1969 |
Pulmonary tuberculosis in patient on intermittent haemodialysis.
Topics: Adult; Aminosalicylic Acids; Female; Humans; Isoniazid; Kidney Failure, Chronic; Renal Dialysis; Str | 1968 |